ASCIDIAN THERAPEUTICS
Ascidian Therapeutics is redefining the treatment of disease by rewriting RNA. By editing exons at the RNA level, Ascidian therapies enable precise post-transcriptional editing of genes, resulting in full-length, functional proteins at the right levels, in the right cells, at the right time. With active discovery and preclinical programs in ophthalmology, neurological and neuromuscular disorders, and other rare diseases, Ascidian is opening new therapeutic possibilities for patients in need of breakthroughs.
ASCIDIAN THERAPEUTICS
Social Links:
Industry:
Biotechnology Genetics Medical Therapeutics
Founded:
2020-01-01
Address:
Boston, Massachusetts, United States
Country:
United States
Website Url:
http://www.ascidian-tx.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
90 M USD
Technology used in webpage:
HSTS CrUX Dataset Amazon Virginia Region CrUX Top 10m CloudFront Ruby On Rails Token Ruby On Rails HCaptcha Out Dated Browser Onehub
Similar Organizations
Ambys Medicines
Ambys Medicines is a biotechnology company focused on discovering and developing regenerative and restorative therapies.
Beam Therapeutics
Beam Therapeutics is a biotechnology company developing precision genetic medicines through the use of base editing technology.
Carisma Therapeutics
Carisma Therapeutics is a biotechnology company developing cellular immunotherapies to treat solid tumors.
Imvax
Imvax is a biotechnology company focused on the development of novel patient-specific vaccines and immunotherapy strategies.
Spark Therapeutics
Spark Therapeutics is focused on the development of gene therapy.
Tango Therapeutics
Tango Therapeutics is a biotechnology company that is developing next generation cancer therapies.
Tessera Therapeutics
Tessera Therapeutics is a biotechnology company that focuses on a new category of genetic medicines.
TruMe Labs
TruMe Labs is a biotechnology research firm that focuses on the discovery of biological age.
Current Employees Featured
Founder
Investors List
Apple Tree Partners
Apple Tree Partners investment in Series A - Ascidian Therapeutics
Apple Tree Partners
Apple Tree Partners investment in Series A - Ascidian Therapeutics
Apple Tree Partners
Apple Tree Partners investment in Seed Round - Ascidian Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2023-03-20 | Ascidian Therapeutics Appoints Jay A. Barth, M.D., as Chief Medical Officer |
Official Site Inspections
http://www.ascidian-tx.com Semrush global rank: 1.78 M Semrush visits lastest month: 12.64 K
- Host name: 47.119.215.35.bc.googleusercontent.com
- IP address: 35.215.119.47
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "Ascidian Therapeutics"
Ascidian Therapeutics - Crunchbase Company Profile
Ascidian Therapeutics is redefining the treatment of disease by rewriting RNA. By editing exons at the RNA level, Ascidian therapies enable precise post-transcriptional editing of genes, resulting in full-length, functional proteins at …See details»
Team | Ascidian Therapeutics
Ascidian therapeutics 80 guest street fourth floor boston ma 02135 atp is developing the next generation of transformative life sciences companies.See details»
Vision | Ascidian Therapeutics
Ascidian Therapeutics is a biotechnology company developing exon-editing RNA therapeutics to target the underlying causes of disease. By harnessing the RNA splicing machinery of a cell and combining it with large-scale DNA and RNA …See details»
Ascidian Therapeutics, Inc. Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Ascidian Therapeutics, Inc. of Boston, MA. Get the latest business insights from Dun & Bradstreet.See details»
Ascidian Company Profile 2024: Valuation, Funding
Ascidian General Information Description. Operator of a biotechnology company intended to design exon-editing RNA therapeutics to target the underlying causes of disease. The company excises disease-causing genes and replaces them …See details»
Ascidian Therapeutics, Inc.
Nov 1, 2024 Explore Ascidian Therapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, 2 clinical trials, 37 news, Disease Domain:Nervous System Diseases, …See details»
Ascidian Therapeutics - LinkedIn
Ascidian Therapeutics is redefining the treatment of disease by rewriting RNA. By editing exons at the RNA level, Ascidian therapies enable precise post-transcriptional editing of genes, resulting ...See details»
Ascidian Therapeutics - Company Profile & Staff Directory
Ascidian Therapeutics is redefining the treatment of disease by rewriting RNA. By editing exons at the RNA level, Ascidian therapies enable precise post-transcriptional editing of genes, …See details»
Current Openings at Ascidian Therapeutics - Pharma Fan
We are seeking a VP of Regulatory Affairs, reporting to our Chief Medical Officer, to play a lead role in building out our Regulatory organization. You will be responsible for all regulatory …See details»
Roche partners with Ascidian Therapeutics to develop gene …
Jun 18, 2024 Ascidian will receive an initial payment of $42 million and up to $1.8 billion in research, clinical, and commercial milestone payments. It is also eligible to receive royalties on …See details»
Ascidian Therapeutics Strengthens Leadership Team
Neurological targets. The per-target agreement enables Ascidian to pursue additional internal and collaborative programs within neurology and other therapeutic areas. For more information, …See details»
FDA批准首个RNA编辑疗法IND - 知乎 - 知乎专栏
2024年1月30日，美国生物技术公司Ascidian Therapeutics宣布其在研RNA外显子编辑疗法ACDN-01的IND申请已经获得美国FDA的许可，并被授予快速通道资格。 FDA批准首个RNA编辑疗 …See details»
Ascidian Therapeutics Launches to Rewrite RNA - Retinal …
A current list of the Ascidian leadership team and Board of Directors can be seen at ascidian-tx.com. About ATP Founded in 1999, ATP is a leader in life sciences venture capital, with …See details»
Terms of Use | Ascidian Therapeutics
Oct 10, 2022 With respect to User Content that you Transmit to the Site, you grant Ascidian a perpetual, worldwide, royalty-free, non-exclusive license to use, copy, excerpt, reproduce, …See details»
IND Cleared for First RNA Exon Editor Therapy, Trial to ... - CGTlive™
Feb 15, 2024 The FDA has cleared Ascidian Therapeutics’ investigational new drug application for ACDN-01, permitting evaluation of the RNA exon editor therapy in a phase 1 trial in people …See details»
Ascidian Therapeutics Email Format | ascidian-tx.com Emails
The most common Ascidian Therapeutics email format is [first_initial][last] (ex. [email protected]), which is being used by 98.0% of Ascidian Therapeutics work email addresses. Other …See details»
Ascidian Life | Ascidian Therapeutics
Ascidian life – A collaborative ecosystem At Ascidian Therapeutics, we are grounded in our vision to translate discoveries into life-changing medicines for patients. Everyone on the Ascidian …See details»
@AscidianTx | X
The latest posts from @AscidianTxSee details»
Ascidian Therapeutics Announces Three Key Development Team …
Apr 11, 2023 Ascidian Therapeutics Announces Three Key Development Team Appointments as It Advances Its Lead Program Toward the Clinic ... [email protected] Heather Shea …See details»